This approach resulted in enhanced CAR expansion, strong and selective tumoricidal activity against several CD7-expressing cell lines (Jurkat, CCRF, MOLT-4, Sup-T1, and Hut78), as well as against human T-ALL samples and xenograft models with variable levels of CD7 expression [43]. The gene discussed is CD7; the disease is acute lymphoblastic leukemia.